L
Lut Van Damme
Researcher at Bill & Melinda Gates Foundation
Publications - 39
Citations - 2925
Lut Van Damme is an academic researcher from Bill & Melinda Gates Foundation. The author has contributed to research in topics: Population & Pre-exposure prophylaxis. The author has an hindex of 19, co-authored 39 publications receiving 2636 citations. Previous affiliations of Lut Van Damme include Conrad Hotels & FHI 360.
Papers
More filters
Journal ArticleDOI
Preexposure Prophylaxis for HIV Infection among African Women
Lut Van Damme,Amy Corneli,Khatija Ahmed,Johan Lombaard,Saidi Kapiga,Mookho Malahleha,Rachel Manongi,Jacob Onyango,Lucky Temu,Modie Constance Monedi,Mankalimeng Makanda,Lisa Saylor,Haddie Kiernan,Stella Kirkendale,Christina Wong,Robert M. Grant,Angela D. M. Kashuba,Kavita Nanda,Justin Mandala,Katrien Fransen,Jennifer Deese,Tania Crucitti,Timothy D Mastro,Douglas Taylor +23 more
TL;DR: Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo, and drug adherence appeared to be low.
Journal ArticleDOI
Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis
Charles S. Morrison,Pai Lien Chen,Cynthia Kwok,Jared M. Baeten,Joelle Brown,Angela M. Crook,Lut Van Damme,Sinead Delany-Moretlwe,Suzanna C. Francis,Barbara Friedland,Richard J. Hayes,Renee Heffron,Saidi Kapiga,Quarraisha Abdool Karim,Stephanie Karpoff,Rupert Kaul,R. Scott McClelland,Sheena McCormack,Nuala McGrath,Landon Myer,Helen Rees,Ariane van der Straten,Deborah Watson-Jones,Janneke van de Wijgert,Randy M. Stalter,Nicola Low +25 more
TL;DR: In a meta-analysis of individual participant data, Charles Morrison and colleagues explore the association between hormonal contraception use and risk of HIV infection in sub-Saharan Africa.
Journal ArticleDOI
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
Amy Corneli,Jennifer Deese,Meng Wang,Doug Taylor,Khatija Ahmed,Kawango Agot,Johan Lombaard,Rachel Manongi,Saidi Kapiga,Angela D. M. Kashuba,Lut Van Damme +10 more
TL;DR: Adherence to the study product was insufficient to demonstrate the effectiveness of FTC/TDF in 2 PrEP clinical trials conducted among women, but further analyses of adherence in these studies may inform PrEP demonstration projects and future HIV prevention clinical trials.
Journal ArticleDOI
Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent
Jan Balzarini,Lieve Naesens,Eric Verbeken,Marie Laga,Lut Van Damme,Michael A. Parniak,Lieve Van Mellaert,Jozef Anné,Erik De Clercq +8 more
TL;DR: The virus that emerged under 0.05% UC-781 remained highly sensitive to the NNRTI, includingUC-781, in cell culture, suggesting a lack of resistance development under the authors' experimental conditions.
Journal ArticleDOI
Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial
Amy Corneli,Brian Perry,Kevin McKenna,Kawango Agot,Khatija Ahmed,Jamilah Taylor,Fulufhelo Malamatsho,Jacob Odhiambo,Joseph Skhosana,Lut Van Damme +9 more
TL;DR: Concerns about the investigational nature of the drug being tested and side effects were the prominent reasons reported for nonadherence, and concerns about the study pill and discouragement from others seemed to have influencedNonadherence considerably.